Swiss Software Stock News

Why this new SMA launch matters for Partners Group Holding (SWX:PGHN) BlackRock and Partners Group Holding (SWX:PGHN) have introduced a multi alternatives separately managed account solution that packages private equity, private credit, and real assets access for financial advisors in a single, streamlined offering. See our latest analysis for Partners Group Holding. The new SMA launch comes after a weaker recent stretch for the shares, with a 7 day share price return showing a 6.49% decline...

If you have been wondering whether Roche Holding's current share price really lines up with its underlying worth, this article walks you through the key numbers that matter. Over the short term the stock has been relatively steady, with a 0.2% decline over the last 7 days. The 30 day, year to date and 1 year returns sit at 3.8%, 8.7% and 25.8% respectively, and the 3 year and 5 year figures are 41.4% and 33.3%. Recent coverage of Roche has focused on its position as a global healthcare group...

Executive reshuffle puts leadership focus back on core functions Flughafen Zürich (SWX:FHZN) has kicked off a broad management reshuffle, cutting its Executive Board from seven to six members and confirming the planned exit of Chief People & Communication Officer Manuela Staub in July 2026. See our latest analysis for Flughafen Zürich. At a share price of CHF249.6, Flughafen Zürich has seen a 4.44% 7 day share price return but a 4.22% 30 day share price decline. Its 1 year total shareholder...

The Swatch Group AG recently reported full-year 2025 results, with sales of CHF 6,280 million and net income of CHF 3 million, and affirmed an annual dividend of CHF 4.50 per share payable on May 19, 2026. The decision to maintain the dividend despite much weaker profitability offers a clear signal about management’s confidence in the group’s financial resilience and priorities for rewarding shareholders. We will now examine how the earnings weakness paired with the affirmed dividend shapes...

Julius Bär Gruppe (SWX:BAER) has released its full year 2025 results, reporting net income of CHF 763.7 million and earnings per share lower than the prior year, a key focus for investors. See our latest analysis for Julius Bär Gruppe. At a share price of CHF66.82, Julius Bär Gruppe has delivered a 22.92% 90 day share price return and a 23.34% 1 year total shareholder return, suggesting momentum has been building even as earnings softened and the board proposed an unchanged CHF2.60 dividend...

Earnings, dividend proposal and operating metrics at a glance Swiss Prime Site (SWX:SPSN) has paired its full year 2025 earnings release with a proposed dividend increase and fresh data on portfolio vacancy, acquisitions and asset management inflows, giving investors several angles to reassess the stock. For 2025, the company reported sales of CHF 456.81 million compared with CHF 463.50 million a year earlier. Net income came in at CHF 382.47 million versus CHF 360.25 million, while basic...

Why Givaudan’s latest earnings and dividend matter for shareholders Givaudan (SWX:GIVN) has put fresh numbers on the table, pairing its full year 2025 earnings release with an annual dividend announcement that gives investors clearer insight into both cash returns and recent business performance. See our latest analysis for Givaudan. The latest earnings and dividend announcement comes after a mixed share price stretch, with a 7 day share price return of 3.58% but a 1 year total shareholder...

Vontobel Holding (SWX:VONN) closed FY 2025 with second half revenue of CHF 741.7 million and basic EPS of CHF 2.94, while trailing 12 month revenue came in at CHF 1.43 billion with basic EPS of CHF 4.99, setting a clear benchmark for the latest reporting stretch. The company has seen revenue move from CHF 694.3 million and basic EPS of CHF 2.44 in 2024’s second half to CHF 741.7 million and CHF 2.94 respectively in 2025’s second half, with trailing net income of CHF 280.1 million framing a...

Why the latest ams-OSRAM (SWX:AMS) calls matter for shareholders Recent special and shareholder or analyst calls at ams-OSRAM (SWX:AMS) have put management’s messaging in focus, giving investors fresh commentary to weigh against the company’s current share performance and fundamentals. See our latest analysis for ams-OSRAM. At a share price of CHF8.24, ams-OSRAM’s recent 1-day share price return of 1.29% and 7-day return of 2.30% sit alongside a 90-day share price decline of 17.65% and a...

Novartis AG ( VTX:NOVN ) will increase its dividend from last year's comparable payment on the 12th of March to $3.70...

Why Vontobel’s latest earnings and dividend matter Vontobel Holding (SWX:VONN) has drawn fresh investor attention after reporting higher full year 2025 net income and earnings per share, together with asset under management growth and an affirmed annual dividend of CHF 3.00 per share. See our latest analysis for Vontobel Holding. The earnings and dividend announcement has coincided with a clear upswing in sentiment, with a 3.83% 1 day share price return and a 16.12% 90 day share price return...

Revenue growth event puts Compagnie Financière Tradition (SWX:CFT) in focus Compagnie Financière Tradition (SWX:CFT) caught investor attention after reporting 2025 consolidated revenue growth of 11.4% at constant exchange rates, with the fourth quarter advancing 11.7% on higher transaction volumes across asset classes and regions. See our latest analysis for Compagnie Financière Tradition. At a share price of CHF289.0, Compagnie Financière Tradition has had a mixed shorter term run, with a 1...

Most readers would already know that Burkhalter Holding's (VTX:BRKN) stock increased by 8.1% over the past three...

It's been a good week for Novartis AG ( VTX:NOVN ) shareholders, because the company has just released its latest...

What ABB’s Recent Run Means For Its Valuation ABB’s share price story can look impressive at first glance, so if you are wondering whether the stock still offers value, it helps to separate the headlines from the actual numbers. Over the last week ABB’s return was 0.1%, over the last month it was 9.5%, year to date it was 8.5%, and over the last year it was 36.6%, with a 3 year return of 128.2% and a 5 year return of 204.3%. This raises fair questions about how much of the good news might...

Barry Callebaut (SWX:BARN) is back in focus after reporting a 22% drop in cocoa division sales volume for the quarter ending November 30, citing weak market demand and a tilt toward higher return cocoa segments. See our latest analysis for Barry Callebaut. The latest cocoa volume setback comes after a period of strong momentum in the share price, with a 12.69% 1 month share price return and an 18.16% 3 month share price return contributing to a 45.54% 1 year total shareholder return, even...

Most readers would already be aware that Swiss Prime Site's (VTX:SPSN) stock increased significantly by 15% over the...

Givaudan SA recently reported its full-year 2025 results, with sales of CHF 7,472 million and net income of CHF 1,071 million, and announced an annual dividend of CHF 72.00 per share payable on March 25, 2026. Despite slightly lower net income and earnings per share than the previous year, the decision to raise the dividend highlights management’s willingness to return more cash to shareholders. We will now examine how Givaudan’s decision to increase its annual dividend despite softer...

As the eurozone economy continues its modest recovery, with improved consumer and business confidence, European markets have shown resilience amidst global trade and geopolitical concerns. In this environment, dividend stocks can offer stability and income potential, making them an attractive option for investors looking to navigate the current market dynamics.

Sensirion Holding AG has launched the SCD53, a highly intrinsically stable CO₂ sensor designed to maintain long-term accuracy without manual recalibration or exposure to outdoor air, while offering integrated humidity, temperature and optional pressure compensation in a compact, easily integrated package. By eliminating reliance on automatic baseline calibration and enhancing robustness against dust, vibrations and mechanical stress, the SCD53 directly targets challenging applications such...

As the European markets navigate a landscape marked by earnings optimism amidst trade and geopolitical concerns, the pan-European STOXX Europe 600 Index has shown resilience with modest gains. Against this backdrop, identifying stocks that are trading below their estimated worth can offer potential opportunities for investors seeking value in an environment where confidence is strengthening and economic recovery continues at a steady pace.

Galderma recently announced that the U.S. FDA has accepted its resubmitted Biologics License Application for RelabotulinumtoxinA, a neuromodulator for treating moderate-to-severe frown lines and crow’s feet in adults, following manufacturing process adjustments and backed by large phase III trial data. This milestone builds on Relfydess’s approvals in more than 20 markets and highlights Galderma’s efforts to broaden its injectable aesthetics franchise worldwide. We’ll now examine how the...

Why ARYZTA’s latest guidance is back in focus ARYZTA (SWX:ARYN) drew fresh attention after its 2025 sales and trading statement call on 22 January, alongside new earnings guidance for 2026 that points to revenue growth and improved performance for the year. For you as an investor, that combination of an updated outlook and a recent company communication creates a new reference point for reassessing ARYZTA’s current valuation, recent share price moves and the risks around its 2026 targets. See...

Idorsia has recently announced an exclusive license and supply agreement with EMS S.A. to register and commercialize its insomnia medicine QUVIVIQ (daridorexant) across Latin America, while also presenting long-term data on lucerastat suggesting disease-modifying potential in Fabry disease at the WORLDSymposium. Together, these developments highlight Idorsia’s push to expand QUVIVIQ into new geographies and progress lucerastat toward a defined regulatory path in a rare disease setting. We’ll...